Truist Financial Has Lowered Expectations for Perspective Therapeutics (NYSE:CATX) Stock Price

Perspective Therapeutics (NYSE:CATX) had its price objective decreased by equities researchers at Truist Financial from $21.00 to $10.00 in a research note issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Truist Financial’s target price points to a potential upside of 486.51% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the company. Lifesci Capital raised Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. Scotiabank assumed coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price objective for the company. Brookline Capital Management upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Perspective Therapeutics in a research report on Monday, March 31st. Finally, Royal Bank of Canada decreased their target price on Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating for the company in a research report on Thursday, March 27th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Perspective Therapeutics presently has a consensus rating of “Buy” and an average price target of $13.22.

Perspective Therapeutics Trading Down 5.3 %

Shares of CATX traded down $0.10 on Monday, reaching $1.71. The stock had a trading volume of 103,536 shares, compared to its average volume of 1,009,583. The company has a 50-day simple moving average of $2.77 and a 200-day simple moving average of $5.86. Perspective Therapeutics has a 12-month low of $1.64 and a 12-month high of $19.05.

Insider Buying and Selling

In related news, Director Robert F. Williamson III acquired 38,145 shares of the firm’s stock in a transaction dated Monday, March 31st. The shares were purchased at an average price of $2.14 per share, with a total value of $81,630.30. Following the completion of the purchase, the director now directly owns 108,982 shares of the company’s stock, valued at $233,221.48. This represents a 53.85 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Juan Graham bought 33,333 shares of the firm’s stock in a transaction on Friday, March 28th. The shares were purchased at an average price of $2.25 per share, for a total transaction of $74,999.25. Following the purchase, the chief financial officer now owns 35,354 shares in the company, valued at $79,546.50. This trade represents a 1,649.33 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 115,696 shares of company stock valued at $256,344. 3.52% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. lifted its holdings in shares of Perspective Therapeutics by 221.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock worth $5,788,000 after buying an additional 298,778 shares in the last quarter. State Street Corp lifted its stake in Perspective Therapeutics by 119.6% in the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after purchasing an additional 1,192,812 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Perspective Therapeutics by 1,302.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company’s stock valued at $635,000 after purchasing an additional 44,174 shares during the last quarter. Vontobel Holding Ltd. bought a new position in shares of Perspective Therapeutics during the 4th quarter valued at about $51,000. Finally, Barclays PLC lifted its position in shares of Perspective Therapeutics by 587.9% in the third quarter. Barclays PLC now owns 114,075 shares of the company’s stock worth $1,523,000 after buying an additional 97,493 shares in the last quarter. 54.66% of the stock is owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.